Nabiximols - GW Pharmaceuticals

Drug Profile

Nabiximols - GW Pharmaceuticals

Alternative Names: Cannabidiol/tetrahydrocannabinol; CBD/THC; CBD:THC; Delta-9-tetrahydrocannabinol/cannabidiol; Delta-9-THC/cannabidiol; Dronabinol/cannabidiol; GW 1000; GW-1000-02; Medicinal cannabis - GW Pharmaceuticals; Nabidiolex®/Tetranabinex®; Sativex; Tetrahydrocannabinol/cannabidiol; THC/CBD; THC:CBD

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GW Pharmaceuticals
  • Developer Almirall S.A.; GW Pharmaceuticals; Novartis; Otsuka Pharmaceutical
  • Class Analgesics; Antidementias; Antiemetics; Antiparkinsonians; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies
  • Mechanism of Action Antioxidants; Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Muscle spasticity; Neuropathic pain
  • Phase I/II Glioblastoma
  • No development reported Bladder dysfunction; Stomatitis

Most Recent Events

  • 07 Aug 2018 GW Pharmaceuticals plans to meet with the US FDA to determine MS spasticity regulatory pathway in H2 2018
  • 06 Feb 2018 GW Pharmaceuticals plans a phase III trial for Muscle spasticity in USA
  • 06 Feb 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top